Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
MDGL

MDGL - Madrigal Pharmaceuticals Inc Stock Price, Fair Value and News

$480.74+6.46 (+1.36%)
Market Closed as of 12 Jun 2026, 04:00 pm ET

55/100

MDGL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

55/100

MDGL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

MDGL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MDGL Price Action

Last 7 days

-1.3%

Last 30 days

-7.3%

Last 90 days

8.1%

Trailing 12 Months

61.8%

MDGL RSI Chart

MDGL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MDGL Valuation

Market Cap

11.1B

Price/Earnings (Trailing)

-35.8

Price/Sales (Trailing)

9.78

Price/Free Cashflow

-40.66

MDGL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

MDGL Fundamentals

MDGL Revenue

Revenue (TTM)

1.1B

MDGL Earnings

Earnings (TTM)

-309.4M

Earnings Growth (Yr)

-28.89%

Earnings Growth (Qtr)

-61.16%

MDGL Profitability

Return on Equity

-56.94%

Return on Assets

-25.21%

Free Cashflow Yield

-2.46%

MDGL Investor Care

Shares Dilution (1Y)

3.85%

Diluted EPS (TTM)

-12.77

MDGL Alerts

  • 2 major insider sales recently.
  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20261.1B000
2025316.4M514.6M739.7M958.4M
2024021.5M80.9M181.1M
20209.9M000
201910.0M11.8M11.8M11.0M
20181.2M2.3M4.9M7.7M
2017000558.0K
20160000
20120000
201112.4M9.9M8.2M7.6M
20100101.1M58.0M14.8M
2009000144.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About Madrigal Pharmaceuticals Inc

MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.
 WEBSITEmadrigalpharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES92

Madrigal Pharmaceuticals Inc Frequently Asked Questions

MDGL is the stock ticker symbol of Madrigal Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of Madrigal Pharmaceuticals Inc is 11.08 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, MDGL's PE ratio (Price to Earnings) is -35.8 and Price to Sales (PS) ratio is 9.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MDGL PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Madrigal Pharmaceuticals Inc has provided 0.461 (multiply by 100 for percentage) rate of return.